Keywords: eusa, rapydan, oked, eu, markets, oxford, uk-based
EUSA's Rapydan OKed in 12 EU markets
Article | 17 March 2008
Oxford, UK-based EUSA Pharma says that its Rapydan (70mg lidocaine/70mg tetracaine medicated plaster) has now received marketing authorization in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
